product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
p38δ MAPK (10A8) Rabbit mAb
catalog :
2308
clonality :
monoclonal
host :
rabbit
conjugate :
nonconjugated
clone name :
10A8
reactivity :
human, mouse, rat
application :
western blot, immunoprecipitation
more info or order :
citations: 3
Published Application/Species/Sample/Dilution | Reference |
---|---|
| |
product information
SKU :
2308P
Product-Name :
p38δ MAPK (10A8) Rabbit mAb
Size :
40 ul
Price-(USD) :
123 USD
Species-x-Reactivity :
H, R
Applications :
Immunoprecipitation
Product-Category :
MAP Kinase Signaling
Shipping-Temp :
AMBIENT
Storage-Temp :
-20°C
Product-Type :
Monoclonal Antibody
MW :
43
Host :
Rabbit
Target :
p38-delta MAPK
Primary-Protein :
p38-delta
Alt-Names :
MAP kinase 13,MAP kinase p38 delta,MAPK 13,MAPK13,MGC99536,MK13,Mitogen-activated protein kinase 13,Mitogen-activated protein kinase p38 delta,PRKM13,SAPK4,Stress-activated protein kinase 4,p38delta
more info or order :
company information
Cell Signaling Technology
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.
review
product type
related products
browse more products
- p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb | 4695
- p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Alexa Fluor® 488 Conjugate) | 4780
- p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Alexa Fluor® 647 Conjugate) | 5376
- p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (Biotinylated) | 5013
- p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb (HRP Conjugate) | 4348
questions and comments